Skip to main content
Clinical Trials/NCT07525219
NCT07525219
Not yet recruiting
Phase 3

A Randomized Controlled Trial Comparing Suzetrigine and Acetaminophen for Reducing Pain During Local Anesthetic Infiltration and Head Frame Application

Wake Forest University Health Sciences1 site in 1 country80 target enrollmentStarted: April 1, 2026Last updated:

Overview

Phase
Phase 3
Status
Not yet recruiting
Enrollment
80
Locations
1
Primary Endpoint
Visual Analog Scale (VAS-Anxiety) score

Overview

Brief Summary

Local anesthetic infiltration is a primary source of acute pain during stereotactic procedures.

Detailed Description

Frame placement can be painful even with local numbing medicine. This study compares two oral medications-Suzetrigine (an FDA-approved (January 30, 2025) non-opioid, non-addictive medication used to treat moderate-to-severe acute pain in adults)) and acetaminophen (Tylenol)-to see which is more effective at reducing this pain. Both Tylenol and Suzetrigine are currently being used for pain prevention during head frame placement. This study is being conducted to determine if one offers greater relief than the other.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Double (Participant, Investigator)

Masking Description

Both suzetrigine and acetaminophen will be placed into identical opaque capsules. Suzetrigine capsules will be backfilled with an inert excipient to match the weight and sound of the acetaminophen capsules.

Eligibility Criteria

Ages
21 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients scheduled for a standard of care procedure requiring a stereotactic head frame to be placed

Exclusion Criteria

  • Patients not scheduled for a standard of care procedure requiring a stereotactic head frame to be placed will not be approached

Arms & Interventions

Acetaminophen

Active Comparator

acetaminophen (1000 mg) - is self-administered at home on an empty stomach approximately 1-6 hours prior to the procedure.

Intervention: acetaminophen (Drug)

Suzetrigine

Experimental

Suzetrigine (100mg) - is self-administered at home on an empty stomach approximately 1-6 hours prior to the procedure.

Intervention: Suzetrigine (Drug)

Outcomes

Primary Outcomes

Visual Analog Scale (VAS-Anxiety) score

Time Frame: Baseline

A single consolidated VAS score (0-10) representing the pain experienced during the administration of local anesthetic across all four pin sites. This VAS is administered immediately after the local anesthetic injections are completed. For anxiety-VAS cutoff value = 40: the VAS score is ≥40 in 81% of patients with anxiety (sensitivity); the VAS score is \<40 in 70% of patients without anxiety (specificity); 67% of patients with a VAS score ≥ 40 have anxiety (PPV); 82% of patients with a VAS score \<40 do not have anxiety (NPV).

Visual Analog Scale (VAS-Infiltration) score

Time Frame: Baseline

A single consolidated VAS score (0-10) representing the pain experienced during the administration of local anesthetic across all four pin sites. This VAS is administered immediately after the local anesthetic injections are completed. For anxiety-VAS cutoff value = 40: the VAS score is ≥40 in 81% of patients with anxiety (sensitivity); the VAS score is \<40 in 70% of patients without anxiety (specificity); 67% of patients with a VAS score ≥ 40 have anxiety (PPV); 82% of patients with a VAS score \<40 do not have anxiety (NPV).

Visual Analog Scale (VAS-Pin Tightening) score

Time Frame: Baseline

A single consolidated VAS score (0-10) representing the pain experienced during the administration of local anesthetic across all four pin sites. This VAS is administered immediately after the local anesthetic injections are completed. For anxiety-VAS cutoff value = 40: the VAS score is ≥40 in 81% of patients with anxiety (sensitivity); the VAS score is \<40 in 70% of patients without anxiety (specificity); 67% of patients with a VAS score ≥ 40 have anxiety (PPV); 82% of patients with a VAS score \<40 do not have anxiety (NPV).

Visual Analog Scale (VAS-Anxiety Reassessment) score

Time Frame: Hour 24

A single consolidated VAS score (0-10) representing the pain experienced during the administration of local anesthetic across all four pin sites. This VAS is administered immediately after the local anesthetic injections are completed. For anxiety-VAS cutoff value = 40: the VAS score is ≥40 in 81% of patients with anxiety (sensitivity); the VAS score is \<40 in 70% of patients without anxiety (specificity); 67% of patients with a VAS score ≥ 40 have anxiety (PPV); 82% of patients with a VAS score \<40 do not have anxiety (NPV).

Total Anesthetic Volume

Time Frame: Hour 6

Documentation of the total volume (mL) of local anesthetic infused.

Secondary Outcomes

  • Number of Clinically Significant Vasovagal Episodes(Hour 6)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials